Drugs that suppress TSH or cause central hypothyroidism

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 23, Issue 6, 2009, Pages 793-800

  Haugen, Bryan R ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

central hypothyroidism; dopamine; glucocorticoids; medications; rexinoids; somatostatin; thyroid function; TSH

Indexed keywords

AMINOGLUTETHIMIDE; AMIODARONE; BEXAROTENE; BROMOCRIPTINE; CARBAMAZEPINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; FUROSEMIDE; GLUCOCORTICOID; HEPARIN; HORMONE RECEPTOR STIMULATING AGENT; INTERFERON; INTERLEUKIN 2; IODIDE; LEVOTHYROXINE; METFORMIN; METYRAPONE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OXCARBAZEPINE; PHENYTOIN; PROBENECID; PROPYLTHIOURACIL; REXINOID DERIVATIVE; SOMATOSTATIN DERIVATIVE; SUNITINIB; THIAMAZOLE; THYROID HORMONE; THYROTROPIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACROMEGALY; BODY TEMPERATURE DISORDER; CLINICAL TRIAL; COLD INTOLERANCE; CONTINUOUS INFUSION; CRITICAL ILLNESS; CUSHING SYNDROME; CUTANEOUS T CELL LYMPHOMA; DEPRESSION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; FATIGUE; HORMONE METABOLISM; HUMAN; HYPERPROLACTINEMIA; HYPOPHYSIS TUMOR; HYPOTHALAMUS; HYPOTHYROIDISM; MONITORING; PATHOGENESIS; PROLACTINOMA; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; THYROID FUNCTION; THYROTROPIN BLOOD LEVEL;

AGED; DOPAMINE AGONISTS; GLUCOCORTICOIDS; HUMANS; HYPOTHYROIDISM; LYMPHOMA, T-CELL; MALE; METFORMIN; RETINOID X RECEPTORS; SOMATOSTATIN; TETRAHYDRONAPHTHALENES; THYROTROPIN;

EID: 71749102435     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2009.08.003     Document Type: Review

References (46)

1. Surks M.I., and Sievert R. Drugs and thyroid function. New England Journal of Medicine 333 25 (12-21-1995) 1688-1694
2. de Groot J.W., Zonnenberg B.A., Plukker J.T., et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clinical Pharmacology and Therapeutics 78 4 (2005) 433-438
3. Wilber J.F., and Utiger R.D. The effect of glucocorticoids on thyrotropin secretion. Journal of Clinical Investigation 48 11 (1969) 2096-2103
4. Brabant A., Brabant G., Schuermeyer T., et al. The role of glucocorticoids in the regulation of thyrotropin. Acta Endocrinologica 121 1 (1989) 95-100
5. Samuels M.H. Effects of variations in physiological cortisol levels on thyrotropin secretion in subjects with adrenal insufficiency: a Clinical Research Center Study. The Journal of Clinical Endocrinology and Metabolism 85 4 (2000) 1388-1393
6. Samuels M.H., and McDaniel P.A. Thyrotropin levels during hydrocortisone infusions that mimic fasting-induced cortisol elevations: a Clinical Research Center Study. The Journal of Clinical Endocrinology and Metabolism 82 11 (1997) 3700-3704
7. Nicoloff J.T., Fisher D.A., and Appleman Jr. M.D. The role of glucocorticoids in the regulation of thyroid function in man. Journal of Clinical Investigation 49 10 (1970) 1922-1929
8. John C.D., Christian H.C., Morris J.F., et al. Kinase-dependent regulation of the secretion of thyrotrophin and luteinizing hormone by glucocorticoids and annexin 1 peptides. Journal of Neuroendocrinology 15 10 (2003) 946-957
9. Cintra A., Fuxe K., Wikstrom A.C., et al. Evidence for Thyrotropin-releasing hormone and glucocorticoid receptor-immunoreactive neurons in various preoptic and hypothalamic nuclei of the male rat. Brain Research 506 1 (1-1-1990) 139-144
10. Alkemade A., Unmehopa U.A., Wiersinga W.M., et al. Glucocorticoids Decrease thyrotropin-releasing hormone messenger ribonucleic acid expression in the paraventricular nucleus of the human hypothalamus. The Journal of Clinical Endocrinology and Metabolism 90 1 (2005) 323-327
11. Ohzeki T., Hanaki K., Motozumi H., et al. Efficacy of bromocriptine administration for selective pituitary resistance to thyroid hormone. Hormones Research 39 5-6 (1993) 229-234
12. Morley J.E. Neuroendocrine control of thyrotropin secretion. Endocrine Reviews 2 4 (1981) 396-436
13. Samuels M.H., Henry P., and Ridgway E.C. Effects of dopamine and somatostatin on pulsatile pituitary glycoprotein secretion. The Journal of Clinical Endocrinology and Metabolism 74 1 (1992) 217-222
14. Kok P., Roelfsema F., Frolich M., et al. Bromocriptine reduces augmented thyrotropin secretion in obese premenopausal women. The Journal of Clinical Endocrinology and Metabolism 94 4 (2009) 1176-1181
15. Lewis B.M., Dieguez C., Lewis M.D., et al. Dopamine stimulates release of thyrotrophin-releasing hormone from perfused intact rat hypothalamus via hypothalamic D2-receptors. Journal of Endocrinology 115 3 (1987) 419-424
16. 't Verlaat J.W., Croughs R.J., Hendriks M.J., et al. Bromocriptine treatment of prolactin secreting macroadenomas: a radiological, ophthalmological and endocrinological study. Acta Endocrinologica 112 4 (1986) 487-493
17. Van den B.G., de Zegher F., and Lauwers P. Dopamine and the sick euthyroid syndrome in critical illness. Clinical Endocrinology 41 6 (1994) 731-737
18. Filippi L., Pezzati M., Cecchi A., et al. Dopamine infusion and anterior pituitary gland function in very low birth weight infants. Biology of the Neonate 89 4 (2006) 274-280
19. Reisine T., and Bell G.I. Molecular biology of somatostatin receptors. Endocrine Reviews 16 (1995) 427-442
20. Mannavola D., Persani L., Vannucchi G., et al. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clinical Endocrinology 62 2 (2005) 176-181
21. Hofland L.J., and Lamberts S.W. Somatostatin receptors in pituitary function, diagnosis and therapy. Frontiers of Hormone Research 32 (2004) 235-252
22. Lamberts S.W., Zuyderwijk J., den Holder F., et al. Studies on the conditions determining the inhibitory effect of somatostatin on adrenocorticotropin, prolactin and thyrotropin release by cultured rat pituitary cells. Neuroendocrinology 50 1 (1989) 44-50
23. Murray R.D., Kim K., Ren S.G., et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. The Journal of Clinical Endocrinology and Metabolism 89 6 (2004) 3027-3032
24. Lightman S.L., Fox P., and Dunne M.J. The Effect of SMS 201-995, a long-acting somatostatin analogue, on anterior pituitary function in healthy male volunteers. Scandinavian Journal of Gastroenterology. Supplement 119 (1986) 84-95
25. Hindmarsh P.C., Pringle P.J., Stanhope R., et al. The Effect of a continuous infusion of a somatostatin analogue (Octreotide) for two years on growth hormone secretion and height prediction in tall children. Clinical Endocrinology 42 5 (1995) 509-515
26. Kirkegaard C., Norgaard K., Snorgaard O., et al. Effect of one year continuous subcutaneous infusion of a somatostatin analogue, octreotide, on early retinopathy, metabolic control and thyroid function in Type I (insulin-dependent) diabetes mellitus. Acta Endocrinologica 122 6 (1990) 766-772
27. Colao A., Merola B., Ferone D., et al. Acute and chronic effects of octreotide on thyroid axis in growth hormone-secreting and clinically non-functioning pituitary adenomas. European Journal of Endocrinology 133 2 (1995) 189-194
28. Roelfsema F., and Frolich M. Pulsatile thyrotropin release and thyroid function in acromegalics before and during subcutaneous octreotide infusion. The Journal of Clinical Endocrinology and Metabolism 72 1 (1991) 77-82
29. Duvic M., Martin A.G., Kim Y., et al. Phase 2 and 3 clinical trial of oral bexarotene (targretin capsules) for the treatment of refractory or persistent early-stage cutaneous t-cell lymphoma. Archives of Dermatology 137 5 (2001) 581-593
30. Khuri F.R., Rigas J.R., Figlin R.A., et al. Multi-institutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. Journal of Clinical Oncology 19 10 (5-15-2001) 2626-2637
31. Esteva F.J., Glaspy J., Baidas S., et al. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. Journal of Clinical Oncology 21 6 (3-15-2003) 999-1006
32. Cesario R.M., Klausing K., Razzaghi H., et al. The rexinoid LG100754 is a novel RXR: PPARgamma agonist and decreases glucose levels in vivo. Molecular Endocrinology 15 8 (2001) 1360-1369
33. Shen Q., Cline G.W., Shulman G.I., et al. Effects of rexinoids on glucose transport and insulin-mediated signaling in skeletal muscles of diabetic (Db/Db) mice. Journal of Biological & Chemistry 279 19 (5-7-2004) 19721-19731
34. Ogilvie K.M., Saladin R., Nagy T.R., et al. Activation of the retinoid X receptor suppresses appetite in the rat. Endocrinology 145 2 (2004) 565-573
35. Sherman S.I., Gopal J., Haugen B.R., et al. Central hypothyroidism associated with retinoid x receptor selective ligands. New England Journal of Medicine 340 (1999) 1075-1079
36. Liu S., Ogilvie K.M., Klausing K., et al. Mechanism of selective retinoid x receptor agonist-induced hypothyroidism in the rat. Endocrinology 143 8 (2002) 2880-2885
37. Golden W.M., Weber K.B., Hernandez T.L., et al. Single-dose rexinoid rapidly and specifically suppresses serum thyrotropin in normal subjects. The Journal of Clinical Endocrinology and Metabolism 92 1 (2007) 124-130
38. Sharma V., Hays W.R., Wood W.M., et al. Effects of rexinoids on thyrotrope function and the hypothalamic-pituitary-thyroid axis. Endocrinology 147 3 (2006) 1438-1451
39. Smit J.W., Stokkel M.P., Pereira A.M., et al. Bexarotene Induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid hormones. The Journal of Clinical Endocrinology and Metabolism (4-17-2007)
40. Isojarvi J.I., Myllyla V.V., and Pakarinen A.J. Effects of carbamazepine on pituitary responsiveness to luteinizing hormone-releasing hormone, thyrotropin-releasing hormone, and metoclopramide in epileptic patients. Epilepsia 30 1 (1989) 50-56
41. Miller J., and Carney P. Central hypothyroidism with oxcarbazepine therapy. Pediatrics Neurology 34 3 (2006) 242-244
42. Hirfanoglu T., Serdaroglu A., Camurdan O., et al. Thyroid function and volume in epileptic children using carbamazepine, oxcarbazepine and valproate. Pediatrics International 49 6 (2007) 822-826
43. Verrotti A., Basciani F., Morresi S., et al. Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. Pediatrics Neurology 25 1 (2001) 43-46
44. Vigersky R.A., Filmore-Nassar A., and Glass A.R. Thyrotropin suppression by metformin. The Journal of Clinical Endocrinology and Metabolism 91 1 (2006) 225-227
45. Cappelli C., Rotondi M., Pirola I., et al. TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid, untreated hypothyroid and euthyroid on l-t4 therapy patients. Diabetes Care (6-5-2009)
46. Isidro M.L., Penin M.A., Nemina R., et al. Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroxine replacement therapy. Endocrine 32 1 (2007) 79-82